Data / Drug companies / AvPAK
AvPAK: 344 products in the FDA NDC directory, labeler code 50268
AvPAK (labeler code 50268) lists 344 products in the FDA National Drug Code Directory, covering 179 finished drugs by generic name. By type: 327 prescription drugs, 17 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 27, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 50268
- Products in commercial distribution
- 344
- Packages
- 352
- Finished drugs by generic name
- 179
- Prescription products
- 327
- Over the counter products
- 17
- Controlled substance products
- Schedule II 6, Schedule III 5, Schedule IV 11, Schedule V 7
- Flagged as original packager
- 41 of 41 products that carry the flag
- Started marketing in the last 12 months
- 24
- Products with a marketing end date set
- 2
- Earliest marketing start
- February 25, 2003
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 322 | 93.6% |
| Over the counter monograph drugs | 15 | 4.4% |
| Other unapproved drugs | 6 | 1.7% |
| Authorized generics (NDA) | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 327 | 95.1% |
| Over the counter drugs | 17 | 4.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 143 | 41.6% |
| Tablet, film coated | 80 | 23.3% |
| Capsule | 53 | 15.4% |
| Tablet, extended release | 10 | 2.9% |
| Tablet, film coated, extended release | 9 | 2.6% |
| Solution | 9 | 2.6% |
| Capsule, extended release | 9 | 2.6% |
| Tablet, delayed release | 5 | 1.5% |
| Cream | 5 | 1.5% |
| Solution/ drops | 4 | 1.2% |
| Tablet, coated | 2 | 0.6% |
| Tablet, chewable | 2 | 0.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sirolimus | 50268-827 | Tablet, film coated | Generic drugs (ANDA) | October 27, 2026 |
| Acamprosate Calcium | 50268-028 | Tablet, delayed release | Generic drugs (ANDA) | October 26, 2026 |
| Allopurinol | 50268-031 | Tablet | Generic drugs (ANDA) | October 6, 2026 |
| Allopurinol | 50268-030 | Tablet | Generic drugs (ANDA) | October 6, 2026 |
| Lacosamide | 50268-492 | Tablet | Generic drugs (ANDA) | September 29, 2026 |
| Lacosamide | 50268-491 | Tablet | Generic drugs (ANDA) | September 29, 2026 |
| Tacrolimus | 50268-737 | Capsule | Generic drugs (ANDA) | September 20, 2026 |
| Tacrolimus | 50268-736 | Capsule | Generic drugs (ANDA) | September 20, 2026 |
| Pantoprazole sodium | 50268-727 | Tablet, delayed release | Generic drugs (ANDA) | August 26, 2026 |
| Ursodiol | 50268-864 | Capsule | Generic drugs (ANDA) | July 14, 2026 |
| Carbidopa and Levodopa | 50268-202 | Tablet | Generic drugs (ANDA) | June 23, 2026 |
| Topiramate | 50268-809 | Tablet, film coated | Generic drugs (ANDA) | June 8, 2026 |
| Topiramate | 50268-808 | Tablet, film coated | Generic drugs (ANDA) | June 8, 2026 |
| Topiramate | 50268-807 | Tablet, film coated | Generic drugs (ANDA) | June 8, 2026 |
| Topiramate | 50268-806 | Tablet, film coated | Generic drugs (ANDA) | June 8, 2026 |
| Calcium Acetate | 50268-203 | Capsule | Generic drugs (ANDA) | May 28, 2026 |
| Loratadine | 50268-777 | Tablet | Generic drugs (ANDA) | May 21, 2026 |
| Ramelteon | 50268-822 | Tablet | Generic drugs (ANDA) | May 20, 2026 |
| Abiraterone Acetate | 50268-032 | Tablet | Generic drugs (ANDA) | May 4, 2026 |
| Esomeprazole Magnesium | 50268-272 | Capsule, delayed release | Generic drugs (ANDA) | March 23, 2026 |
| Cinacalcet | 50268-188 | Tablet, film coated | Generic drugs (ANDA) | March 16, 2026 |
| Phenytoin Sodium | 50268-719 | Capsule, extended release | Generic drugs (ANDA) | March 3, 2026 |
| Methotrexate | 50268-554 | Tablet | Generic drugs (ANDA) | January 29, 2026 |
| Amantadine | 50268-036 | Solution | Generic drugs (ANDA) | January 19, 2026 |
| Cyproheptadine Hydrochloride | 50268-201 | Tablet | Generic drugs (ANDA) | October 30, 2025 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.